Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Resources Controls Sanjiu Medical & Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

New Sanjiu has become the majority shareholder after gaining 71.35 percent stake of Sanjiu Medical & Pharmaceutical. New Sanjiu, set up as a consolidated corporation held by Sanjiu Enterprise Group, has been undergoing restructuring since last July. China Resources Enterprise's subsidiary CR Medications Group raised 4 billion yuan ($572 million) to acquire Sanjiu Enterprise Group, effectively making CR Enterprise, which is aggressively pursuing the health business, the real controlling stakeholder of New Sanjiu. Sanjiu Medical, a key local pharmaceutical enterprise, has been in the doldrums for years due to poor strategizing of main shareholder Sanjiu Enterprise. Analysts expect the current equity transfer to boost the drug firm's future development. (Click here for more - Chinese language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts